Apogee Therapeutics to Participate in Upcoming June Conferences
Rhea-AI Summary
Apogee Therapeutics (Nasdaq: APGE) announced management participation in two June 2026 investor conferences.
The company will join the Jefferies Global Healthcare Conference on June 3, 2026 at 11:40 a.m. ET and the Goldman Sachs 47th Annual Global Healthcare Conference on June 10, 2026 at 9:20 a.m. ET. Live and archived webcasts will be accessible on Apogee's investor website.
Positive
- None.
Negative
- None.
News Market Reaction – APGE
In the May 29 session, APGE gained 5.55%, reflecting a notable positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 27 | Strategic financing deal | Positive | -6.1% | Up to $1.3B Blackstone collaboration to fund Phase 3 and commercialization. |
| May 27 | Phase 2 trial data | Positive | -6.1% | Phase 2 APEX trial met all endpoints; mid-dose advancing to Phase 3. |
| May 26 | Data call announcement | Neutral | -6.1% | Planned call to present 16-week Part B data from APEX trial. |
| May 11 | Earnings and pipeline | Positive | +1.9% | Q1 2026 update with $1.3B cash and supportive Phase 2 data. |
| Mar 26 | Equity offering | Negative | -0.8% | Public equity raise of $403M at $70 per share using shelf. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent history shows multiple positive clinical and financing updates followed by a -6.11% move, suggesting a pattern of negative price reaction to ostensibly favorable news, while earnings and offering events aligned more conventionally with their tone.
Over the past few months, Apogee reported several major milestones. On May 27, 2026, it announced a strategic financing collaboration with Blackstone Life Sciences for up to $1.3 billion in largely non-dilutive capital and positive Part B Phase 2 APEX data for zumilokibart, yet the stock moved -6.11%. Earlier in May, Q1 2026 results highlighted a strong cash position of $1.3 billion and supportive Phase 2 data, with a modestly positive reaction. A March 2026 public offering for roughly $403 million saw only a slight decline, indicating markets have recently reacted more negatively to major clinical and financing news than to capital raises.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN FRANCISCO and BOSTON, May 28, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), today announced that members of management will participate at the following investor conferences.
Jefferies Global Healthcare Conference
Date: Wednesday, June 3, 2026
Fireside Time: 11:40 a.m. ET
Goldman Sachs 47th Annual Global Healthcare Conference
Date: Wednesday, June 10, 2026
Fireside Time: 9:20 a.m. ET
A live and archived webcast of the fireside chats will be available via the News & Events page in the Investors section of the Apogee Therapeutics website.
About Apogee
Apogee Therapeutics is a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing in the largest I&I markets, including for the treatment of AD, asthma, EoE, Chronic Obstructive Pulmonary Disease (COPD) and other I&I indications. Apogee’s antibody programs are designed to overcome limitations of existing therapies by targeting well-established mechanisms of action and incorporating advanced antibody engineering to optimize half-life and other properties. Zumilokibart, the company’s most advanced program, is being initially developed for the treatment of AD, which is the largest and one of the least penetrated I&I markets, as well as asthma and EoE. With four validated targets in its portfolio, Apogee is seeking to achieve best-in-class efficacy and dosing through monotherapies and combinations of its novel antibodies. Based on a broad pipeline and depth of expertise, the company believes it can deliver value and meaningful benefit to patients underserved by today’s standard of care. For more information, please visit https://apogeetherapeutics.com.
Investor Contact:
Noel Kurdi
VP, Investor Relations
Apogee Therapeutics, Inc.
noel.kurdi@apogeetherapeutics.com
Media Contact:
Dan Budwick
1AB
dan@1abmedia.com
